JPMorgan downgraded Replimune (REPL) to Underweight from Neutral without a price target The regulatory path forward for RP1 is unclear and potentially challenging, the analyst tells investors in a research note. The firm believes accelerated approval is less likely following the company’s Type A meeting with the FDA earlier this week. JPMorgan now sees potential for Replimune shares to underperform the broader biotech markets.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Replimune Group Completes FDA Meeting on RP1 Application
- Replimune says ‘committed’ to working with FDA to determine path forward for RP1
- Replimune Group Schedules Crucial FDA Meeting for RP1
- REPL Lawsuit Alert! Class Action Lawsuit Against Replimune Group
- Replimune announces Type A meeting scheduled with FDA